See important safety & full prescribing information. Fda approved in mid october Food and drug administration approved adjuvant cemiplimab (libtayo) for adults with cutaneous squamous cell carcinoma who are at a high risk for recurrence after surgery and radiation.
Fda label information for this drug is available at dailymed Libtayo will be a game changer for head and neck squamous cell cancer Basal cell carcinoma (bcc) (a type of skin cancer).
Cemiplimab is a newer cancer treatment that has brought hope to patients with advanced skin and lung cancers It is part of an exciting group of drugs called immune checkpoint inhibitors, which help the body’s immune system fight cancer more effectively Cemiplimab is approved by the u.s Food and drug administration (fda) to treat advanced forms of skin cancers, including cutaneous squamous.
